Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704189 | 0.79 | MAPK1 (0.33) | MAPK1RIPK1POLB | |
| SCHEMBL3871670 | 0.77 | LTA4H (0.34) | — | |
| SCHEMBL7023755 | 0.76 | MAPK1 (0.31) | MAPK1RIPK1POLB | |
| SCHEMBL2140219 | 0.76 | POLB (0.37) | MAPK1RIPK1POLB | |
| SCHEMBL1203380 | 0.76 | MAPK1 (0.31) | MAPK1RIPK1POLB | |
| SCHEMBL2140224 | 0.76 | ALDH1A1 (0.33) | MAPK1RIPK1POLB | |
| SCHEMBL2971324 | 0.71 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL5565787 | 0.71 | POLB (0.30) | POLB | |
| SCHEMBL21095797 | 0.68 | — | — | |
| SCHEMBL7860990 | 0.67 | RIPK1 (0.34) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334099-B2 | Nucleic acid amplification using a reversibly modified oligonucleotide | BI WANLI (US) | 2012-12-18 | — | — | US | claimed |
| EP-2049689-B1 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2011-12-21 | — | — | EP | claimed |
| US-20100021970-A1 | Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide | BI WANLI | 2010-01-28 | — | — | US | claimed |
| EP-2049689-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | Bi, Wanli (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008016562-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2008-02-07 | — | — | WO | claimed |
| EP-3645548-B1 | METHODS FOR PREPARING BILE ACIDS | MEDYTOX INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| CN-111328332-B | Process for the preparation of bile acids | 玫帝托克斯股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220009957-A1 | Methods for Preparing Bile Acids | MEDYTOX INC. (KR) | 2022-01-13 | — | — | US | disclosed |
| CN-106566855-B | Nucleic acid amplification using reversibly modified oligonucleotides | 苏州新海生物科技股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-11161872-B2 | Methods for preparing bile acids | MEDYTOX INC. (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20200369712-A1 | METHODS FOR PREPARING BILE ACIDS | WUXI APPTEC (SHANGHAI) CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| EP-2049689-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | Bi, Wanli (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090047348-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-02-19 | — | — | US | disclosed |
| WO-2008153278-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS -LINK, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153277-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008016562-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1052264-B1 | Process for the synthesis of nucleoside analogs | PFIZER PROD INC (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6271370-B1 | REACTING 2',3'-O-ALKYLIDENE .BETA.-FURANOSYL HALIDE COMPOUND WITH HETEROCYCLE HAVING RING NITROGEN CAPABLE OF FORMING COVALENT BOND WITH ANOMERIC CARBON OF FURANOSE OR FURANOSE ANALOG IN DIMETHYL SULFOXIDE IN PRESENCE OF STRONG BASE | PFIZER INC | 2001-08-07 | — | — | US | disclosed |
| EP-1052264-A2 | Process for the synthesis of nucleoside analogs | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047348-A1 | POLY(ORGANOPHOSPHAZENE) HYDROGELS FOR DRUG DELIVERY, PREPARATION METHOD THEREOF AND USE THEREOF | PHOSPHO1, PGLS, NAPEPLD | MAPK1 3698/4885RIPK1 3970/4885POLB 1370/4885 |
| US-20220009957-A1 | Methods for Preparing Bile Acids | DHCR7, CYP46A1, CYP27A1 | MAPK1 2189/4885RIPK1 4251/4885POLB 1506/4885 |
| US-20200369712-A1 | METHODS FOR PREPARING BILE ACIDS | DHCR7, CYP46A1, CYP27A1 | MAPK1 2189/4885RIPK1 4251/4885POLB 1506/4885 |
| US-11161872-B2 | Methods for preparing bile acids | DHCR7, CYP46A1, CYP27A1 | MAPK1 2189/4885RIPK1 4251/4885POLB 1506/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | MAPK1 1476/4885RIPK1 4650/4885POLB 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.